Anifrolumab, a relatively recent monoclonal antigen, is sparking considerable hope within the scientific community as a potential option for various immune-related ailments. This unique agent targets the interferon https://bookmark-dofollow.com/story28388216/anifrolumab-a-promising-therapy-for-self-reactive-diseases